<VariationArchive VariationID="2446447" VariationName="NM_005629.4(SLC6A8):c.856del (p.Leu286fs)" VariationType="Deletion" Accession="VCV002446447" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-15" DateCreated="2023-04-09" MostRecentSubmission="2024-04-06">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2421577" VariationID="2446447">
      <GeneList>
        <Gene Symbol="SLC6A8" FullName="solute carrier family 6 member 8" GeneID="6535" HGNC_ID="HGNC:11055" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="153687926" stop="153696593" display_start="153687926" display_stop="153696593" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="152953751" stop="152962047" display_start="152953751" display_stop="152962047" Strand="+" />
          </Location>
          <OMIM>300036</OMIM>
          <Haploinsufficiency last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SLC6A8">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SLC6A8">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_005629.4(SLC6A8):c.856del (p.Leu286fs)</Name>
      <CanonicalSPDI>NC_000023.11:153693116:CCC:CC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="152958572" stop="152958572" display_start="152958572" display_stop="152958572" variantLength="1" positionVCF="152958571" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="153693117" stop="153693117" display_start="153693117" display_stop="153693117" variantLength="1" positionVCF="153693116" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>NM_001142805.2:c.856del</Name>
      </OtherNameList>
      <ProteinChange>L171fs</ProteinChange>
      <ProteinChange>L286fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.152958574del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.152958574del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.153693119del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.153693119del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012016.2" sequenceAccession="NG_012016" sequenceVersion="2" change="g.9823del">
            <Expression>NG_012016.2:g.9823del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001142805.2" sequenceAccession="NM_001142805" sequenceVersion="2" change="c.856del">
            <Expression>NM_001142805.2:c.856del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001136277.1" sequenceAccession="NP_001136277" sequenceVersion="1" change="p.Leu286fs">
            <Expression>NP_001136277.1:p.Leu286fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001142806.1" sequenceAccession="NM_001142806" sequenceVersion="1" change="c.511del">
            <Expression>NM_001142806.1:c.511del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001136278.1" sequenceAccession="NP_001136278" sequenceVersion="1" change="p.Leu171fs">
            <Expression>NP_001136278.1:p.Leu171fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_005629.4" sequenceAccession="NM_005629" sequenceVersion="4" change="c.856del" MANESelect="true">
            <Expression>NM_005629.4:c.856del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_005620.1" sequenceAccession="NP_005620" sequenceVersion="1" change="p.Leu286fs">
            <Expression>NP_005620.1:p.Leu286fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_005629.4(SLC6A8):c.856del (p.Leu286fs) AND Creatine transporter deficiency" Accession="RCV003159281" Version="2">
        <ClassifiedConditionList TraitSetID="3187">
          <ClassifiedCondition DB="MedGen" ID="C1845862">Creatine transporter deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2024-02-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-04-09" MostRecentSubmission="2024-04-06">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/7b5ead04-0f52-4dff-b516-8e3f1be48bdf</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="3187" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1686" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency, X-linked</ElementValue>
                <XRef ID="Creatine+Deficiency%2C+X-Linked/2001" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mental retardation , X-linked with seizures, short stature and midface hypoplasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mental retardation , X-linked, with creatine transport deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">X-linked creatine transporter deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">X-linked creatine deficiency syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SLC6A8-Related Creatine Transporter Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CREATINE TRANSPORTER DEFECT</ElementValue>
                <XRef Type="MIM" ID="300352" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Creatine transporter deficiency</ElementValue>
                <XRef ID="MONDO:0010305" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CEREBRAL CREATINE DEFICIENCY SYNDROME 1</ElementValue>
                <XRef Type="MIM" ID="300352" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0010" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="300036.0004" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS1</ElementValue>
                <XRef Type="MIM" ID="300352" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1608" />
                <XRef ID="1608" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <XRef ID="52503" DB="Orphanet" />
              <XRef ID="C1845862" DB="MedGen" />
              <XRef ID="MONDO:0010305" DB="MONDO" />
              <XRef Type="MIM" ID="300352" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="7195912" SubmissionDate="2024-04-04" DateLastUpdated="2024-04-06" DateCreated="2023-04-09">
        <ClinVarSubmissionID localKey="7b5ead04-0f52-4dff-b516-8e3f1be48bdf" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003852672" DateUpdated="2024-04-06" DateCreated="2023-04-09" Type="SCV" Version="2" SubmitterName="ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen" OrgID="508816" OrganizationCategory="consortium" OrgAbbreviation="ClinGen CCDS VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-10">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/7b5ead04-0f52-4dff-b516-8e3f1be48bdf</URL>
          </Citation>
          <Comment>The NM_005629.4:c.856del (p.Leu286TrpfsTer22) variant in SLC6A8 is a frameshift variant predicted to cause a premature stop codon, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). One male patient has been rreported with elevated urine creatine/creatinine ratio (PMID: 23660394) (PP4). This variant is absent in gnomAD v2.1.1. (PM2_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for creatine transporter deficiency. SLC6A8-specific ACMG/AMP criteria met, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): PVS1, PP4, PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP on March 9, 2023)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">X-linked inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen_CCDS_ACMG_Specifications_SLC6A8_v1.1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/qrdrqmt7/clingen_ccds_acmg_specifications_slc6a8_v1.1.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC6A8" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_001142805.2:c.856del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.11:g.153693119del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0010305" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13004156</SubmissionName>
          <SubmissionName>SUB14358917</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7195912" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0010305" MappingRef="MONDO">
        <MedGen CUI="C1845862" Name="Creatine transporter deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

